Biolife Solutions (BLFS) Current Deferred Revenue (2010 - 2023)

Biolife Solutions (BLFS) has 14 years of Current Deferred Revenue data on file, last reported at $422000.0 in Q1 2023.

• On a quarterly basis, Current Deferred Revenue fell 52.85% year-over-year to $422000.0 in Q1 2023; TTM through Mar 2023 was $422000.0, a 52.85% decrease from a year earlier, with the FY2022 full-year figure at $548000.0, down 32.68% from the prior year.
• Current Deferred Revenue for Q1 2023 stood at $422000.0, down from $548000.0 in the prior quarter.
• Over the last five years, Current Deferred Revenue for BLFS reached as high as $944000.0 in Q2 2021 and fell as low as $324000.0 in Q4 2019.
• Historically, Current Deferred Revenue has averaged $646363.6 across 5 years, with a median of $662000.0 in 2021.
• Across the five-year window, Current Deferred Revenue jumped 187.35% in 2020 and sank 54.34% in 2022, its largest moves.
• Year by year, Current Deferred Revenue stood at $324000.0 in 2019, then soared by 187.35% to $931000.0 in 2020, then retreated by 12.57% to $814000.0 in 2021, then tumbled by 32.68% to $548000.0 in 2022, then retreated by 22.99% to $422000.0 in 2023.
• Per Business Quant data, the three most recent Current Deferred Revenue figures were $422000.0 in Q1 2023, $548000.0 in Q4 2022, and $429000.0 in Q3 2022.